Alkermes plc (ALKS)
| Market Cap | 4.63B |
| Revenue (ttm) | 1.59B |
| Net Income (ttm) | 214.72M |
| Shares Out | 166.88M |
| EPS (ttm) | 1.23 |
| PE Ratio | 22.55 |
| Forward PE | 12.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,244,203 |
| Open | 27.95 |
| Previous Close | 27.88 |
| Day's Range | 27.55 - 27.95 |
| 52-Week Range | 22.01 - 33.71 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 33.50 (+20.76%) |
| Earnings Date | Feb 15, 2024 |
About ALKS
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in the fields of neuroscience and oncology in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products focused on alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of product candidates in development for neurological disorders and cancer. Its marketed products include ARISTADA, an intramuscular injectable susp... [Read more]
Financial Performance
In 2022, Alkermes's revenue was $1.11 billion, a decrease of -5.28% compared to the previous year's $1.17 billion. Losses were -$158.27 million, 228.6% more than in 2021.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ALKS stock is "Buy." The 12-month stock price forecast is $33.5, which is an increase of 20.76% from the latest price.
News
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
DUBLIN , Dec. 14, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Irelan...
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN , Nov. 21, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences. Piper Sandler 3...
Alkermes Completes Separation of Oncology Business
— Alkermes Emerges as Pure-Play, Profitable Neuroscience Company — — Alkermes Provides Updated Financial Expectations for 2023 — DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS...
Alkermes to Participate in the Jefferies London Healthcare Conference
DUBLIN , Nov. 7, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, Nov. 14,...
Alkermes Announces Effectiveness of Mural Oncology Form 10 Registration Statement
DUBLIN , Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was d...
Alkermes plc Reports Third Quarter 2023 Financial Results
— Third Quarter Revenues of $380.9 Million; Net Sales of Proprietary Products Increased Approximately 16% Year-Over-Year — — GAAP Net Income of $47.8 Million and Non-GAAP Net Income of $109.5 Million ...
Alkermes Presents First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
— Initial ALKS 2680 Data Demonstrated Dose-Dependent, Significantly Improved Sleep Latency Compared to Placebo in Narcolepsy Type 1 — — ALKS 2680 Was Generally Well Tolerated at All Doses Tested...
Alkermes to Report Third Quarter Financial Results on October 25, 2023
DUBLIN , Oct. 18, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Mural Oncology to Host Investor Webcast on October 17
— Event to be Webcast on Tuesday, October 17 at 11:00 a.m. ET — DUBLIN , Oct. 10, 2023 /PRNewswire/ -- Mural Oncology plc, the publicly-traded oncology company that Alkermes plc (Nasdaq: ALKS) plans...
Alkermes to Present First Clinical Data for Orexin 2 Receptor Agonist ALKS 2680 at World Sleep Congress
— Oral Presentation to Include Initial Clinical Proof-of-Concept Data in Patients With Narcolepsy Type 1 for ALKS 2680, the Company's Investigational Orexin 2 Receptor Agonist — DUBLIN , Oct. 10, 2023...
Alkermes Presents Clinical and Real-World Data at 36th Annual Psych Congress
— Poster Presentations Highlight Company's Broad Research Commitment to Serious Mental Illness, Addiction and Narcolepsy — DUBLIN , Sept. 11, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ann...
Alkermes Announces Launch of 6th Annual Alkermes Pathways Research Awards® Program
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Application Period to Run From Sept. 15, 2023 Through Nov. 30, 2023 — DUBLIN , Sept.
Alkermes Announces Recipients of 2023 Alkermes Inspiration Grants® Program
– Competitive Grants Program Awards Funding to 11 Innovative Programs Focused on People Living with Addiction, Serious Mental Illness or Cancer – DUBLIN , Aug. 31, 2023 /PRNewswire/ -- Alkermes plc (N...
Alkermes shares surge after settlement with Teva on alcohol dependence treatment
Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Teva Pharmaceuticals USA Inc. TEVA, relating to Vivit...
Alkermes Announces Settlement With Teva Related to VIVITROL® Patent Litigation
— Company Grants Teva a License to Market Generic VIVITROL Beginning in January 2027 — DUBLIN, Aug. 30, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that the company entered into ...
Alkermes plc Reports Second Quarter 2023 Financial Results
— Second Quarter Revenues of $617.4 Million Reflect Strong Performance of Proprietary Product Portfolio and Reinstatement of Long-Acting INVEGA® Product Royalties — — Net Sales of Proprietary Products...
Alkermes to Report Second Quarter Financial Results on July 26, 2023
DUBLIN , July 19, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders
No Sarissa Nominees Elected by Shareholders DUBLIN , June 29, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) (the Company) today announced that, at the Company's 2023 Annual General Meeting of Share...
Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today released the following letter to shareholders of Alkermes plc (NASDAQ: ALKS): June 28, 2023 Dear Fellow Alkermes Shar...
Sarissa Issues Presentation Highlighting Sarissa Nominees Are Qualified to Create Value for Alkermes Shareholders
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today issued a presentation detailing the need for shareholder representation on the board of Alkermes plc (NASDAQ: ALKS) a...
Recently-Appointed Independent Directors of Alkermes Issue Open Letter to Shareholders
Recommend Shareholders Vote "For" Alkermes' Seven Director Nominees On Company's White Proxy Card DUBLIN , June 26, 2023 /PRNewswire/ -- Today, seven of the recently-appointed independent directors of...
Independent Proxy Advisory Firm ISS Agrees With Sarissa Capital That Shareholders' Interests Would Be Best Served With Direct Shareholder Representation on the Alkermes Board
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following additional statement regarding the recent report on Alkermes plc (NASDAQ: ALKS) issued by independ...
Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote "FOR" All Seven of the Company's Highly Qualified Director Nominees
Supports Alkermes' Existing Board and Notes Strong Positive Momentum Shares Board's Belief that Sarissa's Nominees Would Not Be Additive to the Board Notes Alkermes Board is "sufficiently independen...
Independent Proxy Advisory Firm ISS Concludes That Sarissa Capital Has Made a Compelling Case for Change to the Alkermes Board
GREENWICH, Conn.--(BUSINESS WIRE)--Sarissa Capital Management LP (“Sarissa”) today made the following announcement regarding the conclusion reached by independent proxy advisory firm ISS that Sarissa ...
Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees' Election to Alkermes Board
Recognizes Alkermes' Value Enhancement Plan, Board Refreshment and Business Momentum Recommends Voting 'FOR' Shane Cooke and Richard Pops and All Unopposed Alkermes Nominees ISS' Flawed Profitability ...